PALI
Palisade Bio, Inc. NASDAQ Listed Mar 30, 2007$2.10
+1.94%
vs $2.06
Mkt Cap $116.9M
52w Low $0.54
69.0% of range
52w High $2.80
50d MA $1.98
200d MA $1.94
P/E (TTM)
-2.0x
EV/EBITDA
—
P/B
0.9x
Debt/Equity
0.0x
ROE
-13.0%
P/FCF
-10.8x
RSI (14)
57.70
ATR (14)
$0.11
Beta
1.47
50d MA
$1.98
200d MA
$1.94
Avg Volume
2.0M
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
5800 Armada Drive · Carlsbad, CA 92008 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23, 2026 | AMC | -0.02 | -0.04 | -100.0% | 1.91 | -0.5% | +4.7% | +0.0% | -2.0% | +2.0% | -11.0% | — |
| Nov 10, 2025 | AMC | -0.32 | -0.38 | -18.8% | 1.77 | -0.6% | +2.8% | +12.1% | -8.3% | +14.4% | -3.3% | — |
| Aug 11, 2025 | AMC | -0.48 | -0.58 | -20.8% | 0.74 | -7.8% | +1.4% | +8.1% | +0.5% | -1.7% | +0.0% | — |
| May 12, 2025 | AMC | -0.84 | -0.47 | +44.0% | 0.77 | +4.0% | -5.1% | -4.3% | -2.6% | +1.0% | +0.2% | — |
| Mar 24, 2025 | AMC | -1.99 | -0.69 | +65.3% | 0.70 | +2.6% | -1.6% | +0.7% | -0.8% | -0.1% | -1.1% | — |
| Nov 12, 2024 | AMC | -3.35 | -2.32 | +30.7% | 2.38 | +3.4% | -7.6% | +19.1% | -3.8% | -5.2% | +1.7% | — |
| Aug 12, 2024 | AMC | -2.93 | -3.32 | -13.3% | 3.66 | -0.3% | +1.1% | -3.2% | +3.6% | +6.2% | -8.4% | — |
| May 13, 2024 | AMC | -4.80 | -4.59 | +4.4% | 6.22 | -3.5% | +0.3% | +2.2% | +1.3% | -1.5% | -8.0% | — |
| Mar 26, 2024 | AMC | -5.17 | -3.75 | +27.5% | 5.59 | +2.0% | +6.1% | +1.0% | -2.3% | -1.9% | +1.7% | — |
| Nov 9, 2023 | AMC | -0.39 | -7.35 | -1784.6% | 7.80 | +2.9% | +1.9% | -0.6% | -1.3% | +1.9% | -1.3% | — |
| Aug 11, 2023 | AMC | -0.45 | -7.95 | -1666.7% | 10.65 | -5.4% | -7.0% | -6.1% | -6.7% | +7.1% | -1.6% | — |
| May 12, 2023 | AMC | -0.72 | -8.10 | -1025.0% | 23.85 | +2.5% | +0.0% | +0.6% | +0.6% | -2.5% | -5.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 23 | Oppenheimer | Initiates | Outperform | $8 | $1.90 | $2.03 | +6.8% | +6.3% | -3.5% | +4.1% | -0.5% | -3.0% |
| May 13 | Brookline Capital | Maintains | Buy → Buy | — | $0.77 | $0.80 | +4.0% | -5.1% | -4.3% | -2.6% | +1.0% | +0.2% |
| Nov 13 | Maxim Group | Maintains | Buy → Buy | — | $2.38 | $2.46 | +3.4% | -7.6% | +19.1% | -3.8% | -5.2% | +1.7% |
| May 1 | Maxim Group | Maintains | Buy → Buy | — | $6.03 | $7.95 | +31.8% | +17.4% | +3.0% | +6.2% | +9.3% | -6.6% |
| Apr 16 | Maxim Group | Maintains | Buy → Buy | — | $4.16 | $8.75 | +110.3% | +42.5% | +11.3% | -23.2% | -7.1% | +4.7% |
| Nov 17 | Maxim Group | Upgrade | Hold → Buy | — | $7.85 | $8.25 | +5.1% | +15.5% | -0.8% | -1.7% | -1.8% | +1.0% |
| May 16 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $23.85 | $23.70 | -0.6% | +0.6% | +0.6% | -2.5% | -5.1% | -1.3% |
| Mar 30 | Maxim Group | Upgrade | Hold → Buy | — | $25.20 | $29.40 | +16.7% | +57.7% | +32.8% | -35.8% | -10.2% | +7.4% |
| Aug 19 | Maxim Group | Downgrade | Buy → Hold | — | $123.08 | $126.75 | +3.0% | +9.7% | -10.4% | +4.0% | +4.4% | +7.3% |
| Feb 2 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $922.50 | $960.00 | +4.1% | -17.1% | -17.5% | +9.9% | +3.7% | +8.3% |
| Aug 31 | Maxim Group | Maintains | Buy → Buy | — | $2047.50 | $2317.50 | +13.2% | +2.9% | -5.0% | +3.4% | -1.1% | +5.9% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | Finley John DavidDir/Off | CEO, CFO | Sell | 146,798 | $2.07 | $303K | 217,555 | -3.90% | +5.18% |
| Jul 7, 2026 | Jones Mitchell LawrenceOff | Chief Medical Officer | Sell | 51,880 | $2.05 | $107K | 94,009 | -3.90% | +5.18% |
| Jul 7, 2026 | Baltera Robert Jr.Dir | — | Buy | 30,000 | $2.03 | $61K | 416,904 | -3.90% | +5.18% |
| Jul 6, 2026 | Baltera Robert Jr.Dir | — | Buy | 20,000 | $2.05 | $41K | 386,904 | -3.90% | +5.18% |
| Jul 2, 2026 | Baltera Robert Jr.Dir | — | Buy | 10,000 | $1.98 | $20K | 366,904 | +1.96% | -3.57% |
| Jul 1, 2026 | Baltera Robert Jr.Dir | — | Buy | 20,000 | $1.98 | $40K | 356,904 | +1.96% | -3.57% |
8-K · 5.02
!!! Very High
Palisade Bio, Inc. -- 8-K 5.02: Executive Change
Jun 11
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Palatin Technologies' UC Phase 2 clinical trial progress is uncertain; investors should monitor enrollment updates closely as trial results are critical to validating its pipeline and stock valuation.
Apr 2
Valuation
Market Cap
$116.9M
Enterprise Value
-$16.5M
P/E (TTM)
-1.98x
Forward P/E
—
PEG Ratio
0.08x
P/B
0.90x
P/S
—
P/FCF
-10.78x
EV/EBITDA
—
Shares Out
55.7M
Financials (TTM)
Revenue
$0
Net Income
-$24.2M
EBITDA
-$25.4M
Free Cash Flow
-$10.8M
Op Cash Flow
-$10.8M
EPS Basic
$-0.30
EPS Diluted
$-1.06
EPS Forward
$-0.20
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$134.3M
Total Liab.
$5.0M
Total Equity
$129.4M
Cash
$133.4M
LT Debt
$0
Book Value/Sh
$2.32
Debt/Equity
0.00x
Current Ratio
28.95
Quick Ratio
28.95
Returns & Growth
ROE
-13.0%
ROA
-12.5%
ROIC
-13.9%
Rev Growth YoY
+0.0%
EPS Growth YoY
+97.1%
Price Returns
2W
-1.4%
1M
+7.3%
3M
+2.5%
6M
+28.8%
12M
+183.7%
Technicals
52W High
$2.80
52W Low
$0.54
50d MA
$1.98
200d MA
$1.94
RSI (14)
57.70
ATR (14)
$0.11
Beta
1.47
Avg Volume
2.0M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$1.50
High
$1.50
Low
$1.50
Median
$1.50
Data updated apr 26, 2026 6:33pm
· Source: financialmodelingprep.com